Detalhe da pesquisa
1.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1885-1898, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33725432
2.
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Vaccine
; 41(23): 3486-3492, 2023 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37149443
3.
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Nat Med
; 27(11): 2032-2040, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34588689
4.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Lancet HIV
; 8(9): e568-e580, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34416193
5.
Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
Vaccine
; 26(2): 215-23, 2008 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-18055072